Lineage Cell Therapeutics, Inc. ( (LCTX) ) has released its Q2 earnings. Here is a breakdown of the information Lineage Cell Therapeutics, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic cell therapies for serious neurological and ophthalmic conditions, utilizing its proprietary cell-based technology platform. In its second quarter 2025 earnings report, Lineage highlighted significant progress in its clinical programs and manufacturing capabilities. The company reported positive 36-month results from its OpRegen cell therapy program, which is being developed in collaboration with Genentech and Roche, showing potential in treating geographic atrophy secondary to age-related macular degeneration. Additionally, Lineage achieved a milestone in its OPC1 program by treating its first chronic spinal cord injury patient with a novel delivery system. Financially, Lineage reported a net loss of $30.5 million for the quarter, primarily due to a non-recurring impairment expense related to its VAC platform. Despite the increased loss, the company maintains a strong cash position of $42.3 million, expected to support operations into the first quarter of 2027. Looking ahead, Lineage remains optimistic about its pipeline and manufacturing capabilities, positioning itself as a compelling partner and investment opportunity in the biotechnology sector.